Holm Graeßner

1.9k total citations
47 papers, 605 citations indexed

About

Holm Graeßner is a scholar working on Genetics, Molecular Biology and Neurology. According to data from OpenAlex, Holm Graeßner has authored 47 papers receiving a total of 605 indexed citations (citations by other indexed papers that have themselves been cited), including 28 papers in Genetics, 12 papers in Molecular Biology and 12 papers in Neurology. Recurrent topics in Holm Graeßner's work include Genomics and Rare Diseases (27 papers), Neurogenetic and Muscular Disorders Research (7 papers) and Parkinson's Disease Mechanisms and Treatments (7 papers). Holm Graeßner is often cited by papers focused on Genomics and Rare Diseases (27 papers), Neurogenetic and Muscular Disorders Research (7 papers) and Parkinson's Disease Mechanisms and Treatments (7 papers). Holm Graeßner collaborates with scholars based in Germany, Netherlands and United Kingdom. Holm Graeßner's co-authors include Biruté Tumiene, Annemieke Aartsma‐Rus, Walter Maetzler, Joaquim J. Ferreira, Matthis Synofzik, Tom Isaacs, Joy Duffen, Josefa Domingos, Frank Larsen and Helen Matthews and has published in prestigious journals such as Nature Medicine, Nature Reviews Drug Discovery and Movement Disorders.

In The Last Decade

Holm Graeßner

44 papers receiving 593 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Holm Graeßner Germany 13 218 168 136 72 72 47 605
Elisabeth Farbu Norway 18 250 1.1× 23 0.1× 176 1.3× 8 0.1× 126 1.8× 40 981
Christoph Schäfer Norway 11 38 0.2× 35 0.2× 84 0.6× 29 0.4× 40 0.6× 22 387
Anke Salmen Switzerland 17 236 1.1× 20 0.1× 107 0.8× 7 0.1× 72 1.0× 91 898
Jesse H. Krijthe Netherlands 9 168 0.8× 12 0.1× 77 0.6× 36 0.5× 19 0.3× 24 414
Arie Gafson United States 15 200 0.9× 11 0.1× 131 1.0× 11 0.2× 68 0.9× 31 626
Naoki Kozuka Japan 12 74 0.3× 31 0.2× 452 3.3× 37 0.5× 52 0.7× 43 677
Stephen Atkins United Kingdom 22 36 0.2× 67 0.4× 146 1.1× 27 0.4× 12 0.2× 64 1.2k
Carolyn Goldschmidt United States 4 107 0.5× 16 0.1× 164 1.2× 7 0.1× 40 0.6× 9 773
Sebastian Schimrigk Germany 22 248 1.1× 34 0.2× 179 1.3× 4 0.1× 65 0.9× 42 1.1k
Florian Lipsmeier Switzerland 18 146 0.7× 7 0.0× 265 1.9× 39 0.5× 82 1.1× 46 859

Countries citing papers authored by Holm Graeßner

Since Specialization
Citations

This map shows the geographic impact of Holm Graeßner's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Holm Graeßner with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Holm Graeßner more than expected).

Fields of papers citing papers by Holm Graeßner

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Holm Graeßner. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Holm Graeßner. The network helps show where Holm Graeßner may publish in the future.

Co-authorship network of co-authors of Holm Graeßner

This figure shows the co-authorship network connecting the top 25 collaborators of Holm Graeßner. A scholar is included among the top collaborators of Holm Graeßner based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Holm Graeßner. Holm Graeßner is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Schüle, Rebecca, Holm Graeßner, Annemieke Aartsma‐Rus, Willeke van Roon‐Mom, & Matthis Synofzik. (2025). Tailored antisense oligonucleotides for ultrarare CNS diseases: An experience-based best practice framework for individual patient evaluation. Molecular Therapy — Nucleic Acids. 36(3). 102615–102615. 1 indexed citations
2.
Jonker, Anneliene Hechtelt, David Dimmock, Alison Bateman-House, et al.. (2025). From roadmap to a sustainable end-to-end individualized therapy pathway. PubMed. 6. 941248964–941248964. 1 indexed citations
3.
Baynam, Gareth, Adam L. Hartman, Prescilla Carrion, et al.. (2024). Global health for rare diseases through primary care. The Lancet Global Health. 12(7). e1192–e1199. 12 indexed citations
4.
Synofzik, Matthis, et al.. (2024). Advancing ASO therapies from development to implementation. Nature Medicine. 30(10). 2725–2726. 3 indexed citations
5.
Morris, Stephen, Julie Vallortigara, Julie Greenfield, et al.. (2023). Impact of specialist ataxia centres on health service resource utilisation and costs across Europe: cross-sectional survey. Orphanet Journal of Rare Diseases. 18(1). 382–382. 4 indexed citations
6.
Martin, Tamara J., et al.. (2023). Local Data Quality Assessments on EHR-Based Real-World Data for Rare Diseases. Studies in health technology and informatics. 302. 292–296. 1 indexed citations
7.
Painous, Cèlia, Marı́a José Martı́, Holm Graeßner, et al.. (2023). Management of rare movement diseases in different world regions. Parkinsonism & Related Disorders. 108. 105286–105286.
8.
Aartsma‐Rus, Annemieke, Willeke van Roon‐Mom, Marlen C. Lauffer, et al.. (2023). Development of tailored splice-switching oligonucleotides for progressive brain disorders in Europe: development, regulation, and implementation considerations. RNA. 29(4). 446–454. 17 indexed citations
9.
Lagorce, David, Leslie Matalonga, Ida Paramonov, et al.. (2023). Phenotypic similarity-based approach for variant prioritization for unsolved rare disease: a preliminary methodological report. European Journal of Human Genetics. 32(2). 182–189. 5 indexed citations
10.
Egmond, Martje E. van, Holm Graeßner, Norbert Kovács, et al.. (2022). Dystonia management across Europe within ERN-RND: current state and future challenges. Journal of Neurology. 270(2). 797–809. 5 indexed citations
11.
12.
Albanese, Alberto, et al.. (2022). Development of a patient journey map for people living with cervical dystonia. Orphanet Journal of Rare Diseases. 17(1). 130–130. 15 indexed citations
13.
Synofzik, Matthis, Willeke van Roon‐Mom, Georg Marckmann, et al.. (2021). Preparing n-of-1 Antisense Oligonucleotide Treatments for Rare Neurological Diseases in Europe: Genetic, Regulatory, and Ethical Perspectives. Nucleic Acid Therapeutics. 32(2). 83–94. 52 indexed citations
14.
Tumiene, Biruté & Holm Graeßner. (2021). Rare disease care pathways in the EU: from odysseys and labyrinths towards highways. Journal of Community Genetics. 12(2). 231–239. 33 indexed citations
15.
Albanese, Alberto, Mark J. Edwards, Holm Graeßner, et al.. (2021). Dystonia Management: What to Expect From the Future? The Perspectives of Patients and Clinicians Within DystoniaNet Europe. Frontiers in Neurology. 12. 646841–646841. 11 indexed citations
16.
Painous, Cèlia, Nienke J.H. van Os, Anna Delamarre, et al.. (2020). Management of rare movement disorders in Europe: outcome of surveys of the European Reference Network for Rare Neurological Diseases. European Journal of Neurology. 27(8). 1493–1500. 14 indexed citations
17.
Münchau, Alexander, Lüdger Schöls, Christine Klein, & Holm Graeßner. (2019). Model für personalisierte Diagnostik und Therapie in der Neurologie – Deutsche Akademie für Seltene Neurologische Erkrankungen. Der Nervenarzt. 90(8). 796–803. 1 indexed citations
18.
Lochmüller, Hanns, Rachel Thompson, Nine Knoers, et al.. (2018). RD-Connect, NeurOmics and EURenOmics: collaborative European initiative for rare diseases. European Journal of Human Genetics. 26(6). 778–785. 37 indexed citations
19.
Godinho, Catarina, Josefa Domingos, A. Santos, et al.. (2016). Erratum to: A systematic review of the characteristics and validity of monitoring technologies to assess Parkinson’s disease. Journal of NeuroEngineering and Rehabilitation. 13(1). 5 indexed citations
20.
Serrano, J. Artur, Frank Larsen, Tom Isaacs, et al.. (2015). Participatory Design in Parkinson's Research with Focus on the Symptomatic Domains to be Measured. Journal of Parkinson s Disease. 5(1). 187–196. 26 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Elisabeth Farbu Breakdown of academic impact, for papers by Christoph Schäfer Breakdown of academic impact, for papers by Anke Salmen Breakdown of academic impact, for papers by Jesse H. Krijthe Breakdown of academic impact, for papers by Arie Gafson Breakdown of academic impact, for papers by Naoki Kozuka Breakdown of academic impact, for papers by Stephen Atkins Breakdown of academic impact, for papers by Carolyn Goldschmidt Breakdown of academic impact, for papers by Sebastian Schimrigk Breakdown of academic impact, for papers by Florian Lipsmeier
Rankless by CCL
2026